Health Care

Prime Medicine insider buys signal CEO confidence in a big biotech win – 1.3 M stock options, rising share price, and growing market sentiment show a promising next phase.

CEO insider sell‑off sparks debate on UniQure’s gene‑therapy outlook, raising questions about management confidence amid strong market gains.

Inovio insider moves reveal a liquidity‑focused strategy: chief scientific officer Humeau Laurent buys and sells RSUs, hinting at short‑term cash needs while still backing the company’s vaccine pipeline.

Insider buying surge at Myriad signals confidence amid volatility: 104,000+ shares purchased, potential upside, and strategic pipeline insights.

UroGen insider buying signals optimism amid strong clinical data: insider purchases, positive sentiment, and upcoming conference highlight potential upside, but investors should watch regulatory risks.

Insider buy of VeraDermics shares at $17 signals confidence ahead of Phase 3 results; 1 % stake may hint at undervaluation and potential upside.

iRhythm insider buying signals cautious optimism amid volatility, as CFO and CEO purchases suggest confidence in AI‑driven growth and near‑term gains.

Alkermes insider trading shows mixed buying and selling, suggesting leadership confidence amid earnings volatility and a potential rebound in the biopharma’s CNS pipeline.

Investor insight: Neuronetics CEO’s recent insider sales are routine tax moves, not a warning of distress—positive cash flow and stable fundamentals keep the stock on track.

VolitionRX insider buys signal management confidence amid a shaky stock, showing a 11% stake shift and potential upside for long‑term investors.